

Oracle Life Sciences CancerMPact

Treatment Architecture

In-depth analysis of oncology treatment practices

Drug utilization is captured for all treatment settings and lines of therapy, and by patient type in tumors where biomarkers have segmented the drug market. Treatment Architecture also provides summaries of pivotal clinical trial results to highlight the benchmark outcomes associated with standard-of-care regimens.

Treatment Architecture is based on online research with direct responses from more than 7,500 healthcare providers across the globe, representing more than 450,000 treated patients monthly. It offers added confidence due to the benefit of global consistency in our research methods, providing for more reliable comparison of treatment trends among the G8 countries.

Treatment data for each tumor is updated once per year in each geography.

Business issues addressed

How do patients progress through different treatment settings, including lines of systemic therapy?

 Understanding the opportunities that exist for patient treatment, including patients who do not currently receive therapy, is critical to maximizing commercial success.

How does treatment vary based on genetic differences and biomarker status?

 Companies with new agents entering an existing biomarker population need to understand the current treatment standards, while new agents seeking to establish a new biomarker niche can gain insight on adoption of diagnostic testing and targeted therapy adoption from existing analogs.

How does treatment vary among the US, Western Europe, Japan, and China?


 Understanding differences in standards of care is critical when designing pivotal development strategies for new products to ensure regulatory and commercial success.

At a glance

Oracle Life Sciences CancerMPact's Treatment Architecture syndicated solution assesses the current clinical management of patients by site and stage for all treatment modalities – including surgical, radiologic and systemic agents, as well as untreated patient populations. It provides in-depth quantitative analysis of oncology treatment practices for up to 31 tumor types in the G8 markets:

- United States
- Western Europe (France, Germany, Italy, Spain, United Kingdom)
- Japan
- China

Oracle Life Sciences can also create similar reports for other global markets or additional tumor types as a custom engagement.





Improving business outcomes through empowered decision making

Oracle Life Sciences CancerMPact is an invaluable and comprehensive oncology decision support resource. It can be utilized for market analysis, strategic planning and identification of commercial opportunities in the U.S., Western Europe, Japan and China. This resource is composed of cloud-based integrated modules: Patient Metrics (Patient Metrics – Core, Patient Metrics – Expanded Markets, PM Dashboards, and Biomarker Analysis), Treatment Architecture, Treatment Architecture Trends, and CancerLandscape.

1. Patient Metrics

Best-in-class cancer epidemiology and proprietary patient calculations for target markets.

Patient Metrics Core – U.S., Western Europe, Japan, China – combines epidemiologic data and analysis to estimate incidence (annual new cases of cancer) by stage; restaged 5-, 10-, or 15-year prevalence (annual surviving cancer patients from up to 15 years prior that accounts for progression to later stages); active disease (estimate of treatment-eligible patients by stage that does not include early-stage patients in remission); and treated patient populations by modality (surgery, radiation, drug therapy, etc.), drug regimens and drug agents.

Patient Metrics Expanded Markets – Combines epidemiologic data and analysis to estimate incidence (annual new cases of cancer) by stage; five-year prevalence (annual surviving cancer patients from up to five years prior; and treatable patients for up to 16 tumor types. Available for Argentina, Brazil, Canada, India, Mexico, Russia, South Korea, Taiwan and Turkey.

PM Dashboards – Interactive, multi-country views of the epidemiology and treatment of cancer, making comparisons across geographies, patients and tumors much easier. PM Dashboards features six interactive dashboards to allow you to more quickly and easily evaluate global trends in cancer epidemiology.

Biomarker Analysis – Expert analysis of key oncology biomarker segments. Biomarker Analysis is a global resource based on a thorough review of literature and recently published data that discusses the current and evolving oncology landscape with regard to biomarker segmentation rates and geographic, survival, ethnic, racial and gender differences.

2. Treatment Architecture

In-depth quantitative analysis of oncology drug and modality utilization across all cancer disease stages.

Treatment Architecture assesses the current clinical management of cancer patients by site and stage for all treatment modalities – including surgical, radiologic and systemic agents, as well as untreated patient populations. Treatment Architecture also provides pivotal clinical trial summaries to highlight the benchmark outcomes contributing to standard-of-care designations. Drug utilization is captured for all treatment settings and lines of therapy and by patient type in tumors where biomarkers have segmented the drug market.

3. Treatment Architecture Trends

Analytics for in-depth exploration of historical treatment patterns.

Treatment Architecture (TA) Trends allows for customized data exploration, powerful analytics, and impactful visualization of a wide variety of treatment data. TA Trends provides historical global treatment patterns allowing for analysis of the impact of market events on share and uptake of drugs and drug classes. A broad set of diagnostics, modality, drug, and outcomes data can be queried and filtered by stage, patient segment, drug technology, target, regimen, physician specialty, physician treatment setting and country.

4. Future Trends and Insights

Expert analysis of the changing oncology competitive landscape with focus on ongoing pivotal clinical trials.

Future Trends and Insights explores potential changes in treatment practices in the U.S., Western Europe and Japan based on a critical evaluation of recently published clinical data, regulatory advances/ setbacks and ongoing pivotal clinical trials. It identifies key trends in each tumor market, which can comprise new product introductions or label expansions of marketed products. It also assesses unmet needs for each cancer while continuously monitoring the competitive environment.

5. CancerLandscape

A visual, comprehensive overview of the oncology drug and trial landscape

CancerLandscape combines and standardizes U.S., EU, and Japan trial registries with other data sources to provide a visual and detailed understanding of the oncology trial landscape by company, tumor, drug and target. Users have the ability to filter on detailed clinical and commercial variables, make quick comparisons, uncover trends, and evaluate trial timing and enrollment. Gain insights about the oncology landscape in detail with a simple interface that is updated on a weekly basis. Clinical and scientific support is provided by the Oracle Life Sciences oncology support team.

The materials in this presentation pertain to Oracle Health, Oracle, Oracle Cerner, and Cerner Enviza which are all wholly owned subsidiaries of Oracle Corporation. Nothing in this presentation should be taken as indicating that any decisions regarding the integration of any EMEA Cerner and/or Enviza entities have been made where an integration has not already occurred.

